Healio

Frexalimab linked to reduction in lesion activity, well tolerated in relapsing MS

Please provide your email address to receive an email when new articles are posted on . A phase 2 study included 129 individuals with MS randomized to receive frexalimab or placebo for 24 weeks.
Healio

Ublituximab reduced brain volume loss by 22%, suppressed new lesion formation

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed data from 1,094 individuals with relapsing MS. At 2 years, treatment with ublituzimab ...
Nasdaq

Roche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trials ...
Seeking Alpha

Roche MS drug reduces brain lesions, meeting goals of phase 2 trial

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said its oral drug fenebrutinib met the main and secondary goals of a phase 2 trial by reducing brain lesions in adults with relapsing forms of multiple sclerosis ...
Business Wire

Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis

–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) ...